Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L523S
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Likely Intramuscular Or Subcutaneous For Ad/L523S (based On Standard Practice; Not Explicitly Stated)
01
Overview
L523S is an immunogenic lung cancer antigen and oncofetal protein that has been investigated as a therapeutic cancer vaccine. It is delivered either as a recombinant DNA plasmid (pVAX/L523S) or via a replication-defective adenoviral vector (Ad/L523S), both encoding the human L523S protein. Upon administration, these vaccines express the L523S antigen in vivo, which may stimulate antibody and cytotoxic T lymphocyte responses against tumor cells expressing L523S. The primary indication explored for this therapy has been non-small cell lung cancer. Development was initially led by GSK and Corixa Corp., with clinical trials evaluating safety and immunogenicity in early-stage non-small cell lung cancer patients[1][2][3][5].
- Other names
- recombinant adenovirus-L523S vaccinerecombinant DNA-L523S vaccine
02
Targets
LCAA (Lung Cancer-Associated Antigen L523S)
Beyond the preview
Go deeper on L523S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L523S.